Band 3
Band 4
About
Provided by Bernardo Martínez Negrete E
Practice Areas
Life Sciences
Projects and Infrastructure
Career
Bernardo is a specialist lawyer with extensive experience in commercial and regulatory aspects of the life sciences and infrastructure industries. He also has experience in project finance and mergers and acquisitions.
In the infrastructure industry, Bernardo advises financial institutions and developers on the construction and financing of infrastructure projects, such as highways, railways, aqueducts, water treatment plants, desalinization plants, government facilities and other major projects through services and construction contracts, concessions and public-private partnerships. In one of his recent work highlights, he advised Abertis Infraestructuras (one of the largest toll roads operators in the world) and GIC (one of the three reserves management entities of Singapore) on their acquisition of Red de Carreteras de Occidente, one of the biggest toll road operators in Mexico. This was one of the largest M&A transactions in Mexico in recent years.
In the life sciences industry, Bernardo advises pharmaceutical companies in M&A transactions and on regulatory aspects related to marketing authorizations, divesture of assets, vaccination projects, public procurement, manufacture, supply and distribution of medicines, human clinical trials, construction and operation of pharmaceutical facilities and commercialization of medicines. One of his recent projects that stands out is his advice to Sanofi in the implementation of the first public private partnership for the manufacturing and commercialization of influenza vaccines in Mexico, a project of paramount relevance to Mexico’s population.
Bernardo undertakes various Pro Bono activities for health-related associations and local communities in Mexico City.
Bernardo has a law degree from Instituto Tecnológico Autónomo de México (1998) and was a foreign associate at Shearman & Sterling in New York (2001).
Bernardo is member of the Compensation and the New Collaboration Model Committees at the Firm.